Metabolic impact of weight loss induced reduction of adipose ACE-2 – Potential implication in COVID-19 infections?Randomized Controlled Trial Published on 2020-12-012022-10-05 Journal: Metabolism: clinical and experimental [Category] SARS, 임상, [키워드] ACE-2 adipose Adipose tissue Affect age analyzed angiotensin BMI cell entry changes in characterized Clamp control group COVID-19 downregulation enzyme expression Glucose improvement insulin insulin resistance Insulin sensitivity Intervention ISI liver metabolic metabolism modulation mRNA expression not affected obesity Potential predicted preserved Randomized receptor reduction Regulation responsible SARS-CoV-2 sensitivity Skeletal muscle subject subjects tissue tissue metabolism Trial was measured was reduced weight weight loss [DOI] 10.1016/j.metabol.2020.154401 PMC 바로가기 [Article Type] Randomized Controlled Trial
TAILoR (TelmisArtan and InsuLin Resistance in Human Immunodeficiency Virus [HIV]): An Adaptive-design, Dose-ranging Phase IIb Randomized Trial of Telmisartan for the Reduction of Insulin Resistance in HIV-positive Individuals on Combination Antiretroviral TherapyTAILoR(인간 면역결핍 바이러스[HIV]의 TelmisArtan 및 InsuLin 내성): 복합 항레트로바이러스 요법을 받는 HIV 양성 환자의 인슐린 내성 감소를 위한 Telmisartan의 적응형 설계, 용량 범위 IIb상 무작위 시험Articles and Commentaries Published on 2020-05-152022-09-06 Journal: Clinical Infectious Diseases: An Official Publicat [Category] Communicable Disease, [키워드] adaptive Analysis antiretroviral drugs Antiretroviral therapy Antiretrovirals ARMS cardiovascular disease check clinical Combination conducted Controlled trial demonstrated Efficacy evaluated fat had no HIV HIV infection homeostasis Human Human immunodeficiency virus identify IIb immunodeficiency virus improvement Improvements index individual Infection insulin insulin resistance Insulin sensitivity interim analysis Intervention investigated ISRCTN liver longitudinal longitudinal analysis measure metabolic abnormalities Metabolic abnormality metabolic disease morbidity and mortality multicenter no difference no differences no significant effect once daily Open-label participant Patient phase plasma Primary outcome primary outcome measure Randomized receiving recruited reduce reduction in Registration resistance Result risk secondary outcome measures significant effect Stage stage II telmisartan Trial with HIV [DOI] 10.1093/cid/ciz589 PMC 바로가기 [Article Type] Articles and Commentaries